248 related articles for article (PubMed ID: 16827113)
1. MIB-1 labelling indices according to clinico-pathological variables in canine mammary tumours: a multivariate study.
De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Dos Santos MS; Rutteman GR; Gärtner Mde F
Anticancer Res; 2006; 26(3A):1821-6. PubMed ID: 16827113
[TBL] [Abstract][Full Text] [Related]
2. E-cadherin expression in canine malignant mammary tumours: relationship to other clinico-pathological variables.
Matos AJ; Lopes C; Carvalheira J; Santos M; Rutteman GR; Gärtner F
J Comp Pathol; 2006; 134(2-3):182-9. PubMed ID: 16545841
[TBL] [Abstract][Full Text] [Related]
3. MUC1 expression in canine malignant mammary tumours and relationship to clinicopathological features.
de Oliveira JT; Pinho SS; de Matos AJ; Hespanhol V; Reis CA; Gärtner F
Vet J; 2009 Dec; 182(3):491-3. PubMed ID: 18948041
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical expression of vascular endothelial growth factor in canine mammary tumours.
Santos AA; Oliveira JT; Lopes CC; Amorim IF; Vicente CM; Gärtner FR; Matos AJ
J Comp Pathol; 2010 Nov; 143(4):268-75. PubMed ID: 20570280
[TBL] [Abstract][Full Text] [Related]
5. The role of CD44 adhesion factor in canine mammary carcinomas.
Madrazo J; García-Fernández RA; García-Iglesias MJ; Durán AJ; Espinosa J; Pérez-Martínez C
Vet J; 2009 Jun; 180(3):371-6. PubMed ID: 18299241
[TBL] [Abstract][Full Text] [Related]
6. Expression and prognostic significance of CK19 in canine malignant mammary tumours.
Gama A; Alves A; Schmitt F
Vet J; 2010 Apr; 184(1):45-51. PubMed ID: 19264518
[TBL] [Abstract][Full Text] [Related]
7. Expression of TopBP1 in canine mammary neoplasia in relation to histological type, Ki67, ERalpha and p53.
Morris JS; Nixon C; King OJ; Morgan IM; Philbey AW
Vet J; 2009 Mar; 179(3):422-9. PubMed ID: 18314357
[TBL] [Abstract][Full Text] [Related]
8. Mutation and overexpression of p53 as a prognostic factor in canine mammary tumors.
Lee CH; Kim WH; Lim JH; Kang MS; Kim DY; Kweon OK
J Vet Sci; 2004 Mar; 5(1):63-9. PubMed ID: 15028887
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors.
Chang CC; Tsai MH; Liao JW; Chan JP; Wong ML; Chang SC
J Am Vet Med Assoc; 2009 Aug; 235(4):391-6. PubMed ID: 19681719
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical analysis of urokinase plasminogen activator and its prognostic value in canine mammary tumours.
Santos A; Lopes C; Marques RM; Amorim I; Ribeiro J; Frias C; Vicente C; Gärtner F; de Matos A
Vet J; 2011 Jul; 189(1):43-8. PubMed ID: 20598596
[TBL] [Abstract][Full Text] [Related]
11. Expression of extracellular matrix metalloproteinase (MMP-9), E-cadherin and proliferation-associated antigen Ki-67 and their reciprocal correlation in canine mammary adenocarcinomas.
Nowak M; Madej JA; Podhorska-Okolow M; Dziegiel P
In Vivo; 2008; 22(4):463-9. PubMed ID: 18712173
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of progesterone and cellular proliferation in canine mammary tumours.
Thuróczy J; Reisvaag GJ; Perge E; Tibold A; Szilágyi J; Balogh L
J Comp Pathol; 2007; 137(2-3):122-9. PubMed ID: 17645888
[TBL] [Abstract][Full Text] [Related]
13. Prognostic relevance of proliferative activity evaluated by Mib-1 immunostaining in node negative breast cancer.
Neri A; Marrelli D; Pedrazzani C; Caruso S; De Stefano A; Mariani F; Megha T; De Marco G; Corso G; Pinto E; Roviello F
Eur J Surg Oncol; 2008 Dec; 34(12):1299-303. PubMed ID: 18164172
[TBL] [Abstract][Full Text] [Related]
14. Expression of E-cadherin, P-cadherin and beta-catenin in canine malignant mammary tumours in relation to clinicopathological parameters, proliferation and survival.
Gama A; Paredes J; Gärtner F; Alves A; Schmitt F
Vet J; 2008 Jul; 177(1):45-53. PubMed ID: 17631398
[TBL] [Abstract][Full Text] [Related]
15. Proliferation indices in spontaneous canine lung cancer: proliferating cell nuclear antigen (PCNA), Ki-67 (MIB1) and mitotic counts.
Griffey SM; Kraegel SA; Madewell BR
J Comp Pathol; 1999 May; 120(4):321-32. PubMed ID: 10208729
[TBL] [Abstract][Full Text] [Related]
16. The relationship between tumour size and expression of prognostic markers in benign and malignant canine mammary tumours.
Ferreira E; Bertagnolli AC; Cavalcanti MF; Schmitt FC; Cassali GD
Vet Comp Oncol; 2009 Dec; 7(4):230-5. PubMed ID: 19891693
[TBL] [Abstract][Full Text] [Related]
17. E-cadherin, beta-catenin, invasion and lymph node metastases in canine malignant mammary tumours.
De Matos AJ; Lopes CC; Faustino AM; Carvalheira JG; Rutteman GR; Gärtner Mde F
APMIS; 2007 Apr; 115(4):327-34. PubMed ID: 17504299
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological prognostic factors in canine mammary tumors.
Pérez Alenza MD; Peña L; Nieto AI; Castaño M
Ann Ist Super Sanita; 1997; 33(4):581-5. PubMed ID: 9616968
[TBL] [Abstract][Full Text] [Related]
19. Sialyl Lewis x expression in canine malignant mammary tumours: correlation with clinicopathological features and E-Cadherin expression.
Pinho SS; Matos AJ; Lopes C; Marcos NT; Carvalheira J; Reis CA; Gärtner F
BMC Cancer; 2007 Jul; 7():124. PubMed ID: 17617904
[TBL] [Abstract][Full Text] [Related]
20. Quantification of VEGF-C expression in canine mammary tumours.
Qiu C; Lin DD; Wang HH; Qiao CH; Wang J; Zhang T
Aust Vet J; 2008 Jul; 86(7):279-82. PubMed ID: 18616481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
